Ann: Opthea secures up to US$170m in non-dilutive financing, page-29

My feeling is that the impetus for a significant reversal will only begin once the company announces it has completed patient recruitment to its phase III trials. That is when the clock effectively start ticking. I have found it interesting that Opthea has not given any updates on patient recruitment even though Megan Baldwin earlier in the piece indicated this would occur. Perhaps this reflects an overall slower recruitment rate than expected even taking into account the impact Covid has played. Anyway it would be nice to be pleasantly surprised as occurred with the phase II trials where patient recruitment came in ahead of projected schedule